Phase I/II Study of Temsirolimus (Torisel) as Novel Therapeutic Drug for Patients With Unresectable Hepatocellular Carcinoma (HCC)- A Correlative Study With Stathmin Over-expression
Phase of Trial: Phase I/II
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Temsirolimus (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jan 2014 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 17 Jul 2013 Planned End Date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.